Announces distribution of approximately 83,000 specimen collection kits to clients SAN DIEGO , Sept. 16, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve
SAN DIEGO , Sept. 9, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostics designed to provide physicians with clinically actionable information to improve the patient outcomes, announces that President and CEO Michael Nall will present at the
SAN DIEGO , Sept. 8, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve patient outcomes, announces it has entered into an agreement with Health Net Federal
SAN DIEGO , Sept. 4, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve patient outcomes, announces that, as a result of the Company's one-for-ten reverse stock
Announces distribution of approximately 46,000 specimen collection kits to clients SAN DIEGO , Aug. 31, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve
SAN DIEGO , Aug. 27, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces that President and CEO Michael Nall will present at the
SAN DIEGO , Aug. 24, 2020 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces the appointment of Michael C. Dugan , M.D.
SAN DIEGO , Aug. 20, 2020 (GLOBE NEWSWIRE) -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces that President and CEO Michael Nall will present at
SAN DIEGO , Aug. 19, 2020 (GLOBE NEWSWIRE) -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces the expansion of its agreement with MultiPlan,
Expands Company's patent portfolio and marks another step in pursuit of worldwide intellectual property protection for proprietary Primer-Switch technology used to detect rare events such as cancer biomarkers found in tissue and liquid biopsies SAN DIEGO , Aug.
